Sustained response to intravenous alendronate in postmenopausal osteoporosis

Bone

Volumn 17, Issue 6, 1995, Pages 517-520

  Vasikaran, S D ^a,b   Khan, S ^b   McCloskey, E V ^b   Kanis, J A ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Alendronate; Biochemical markers; Bone mineral density; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; HYDROXYPROLINE; OSTEOCALCIN; PHOSPHATE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; HYDROXYPROLINE URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUMBAR SPINE; LYMPHOCYTOPENIA; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; CALCIUM; DENSITOMETRY, X-RAY; FEMALE; HUMANS; HYDROXYPROLINE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE;

EID: 0029561513     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/8756-3282(95)00400-9     Document Type: Article

References (25)

1. The acute-phase response after bisphosphonate administration
2. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone
3. Preliminary observations of a form of coherence therapy for osteoporosis
4. Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease
5. An evaluation of serum osteocalcin in Paget's disease of bone and its response to diphosphonate treatment
6. Experimental basis for the use of bisphosphonates in Paget's disease of bone
7. Bisphosphonates
8. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate)
9. Oral bioavailability and dose proportionality of alendronate (aminohydroxybutylidene bisphosphonate) in postmenopausal women
10. The effect of short-term treatment with alendronate upon vertebral density and biochemical markers of bone remodelling in early postmenopausal women
11. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate; a clinical and morphological study
12. Long term follow-up observations on treatment in Paget's disease of bone
13. Future opportunities for bisphosphonates in osteoporosis
14. Rationale for the use of alendronate in osteoporosis
15. The assessment of Vertebral deformity: A method for use in population studies and clinical trials
16. Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients
17. Clinical and laboratory evaluation of a two-site immunoradiometric asay for intact parathyroid hormone
18. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate
19. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone
20. Alendronate treatment of the postmenopausal osteoporotic woman. Effect of multiple dosages on bone mass and bone remodelling
21. Prevention of postmenopausal bone loss by tiludronate
22. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with post menopausal osteoporosis
23. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate): A nonlinear increase of lumbar bone mineral density
24. Intermittent cyclical etidronate treatment of post menopausal osteoporosis